The V Foundation
13
5
8
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 40/100
7.7%
1 terminated/withdrawn out of 13 trials
75.0%
-11.6% vs industry average
0%
0 trials in Phase 3/4
133%
4 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
Role: collaborator
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
Role: collaborator
Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma
Role: collaborator
Targeted Navigation in Hepatocellular Carcinoma (HCC)
Role: collaborator
Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
Role: collaborator
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
Role: collaborator
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
Role: collaborator
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
Role: collaborator
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Role: collaborator
Trial of ProAgio in Advanced/Metastatic Colorectal Cancer
Role: collaborator
Neoadjuvant Atezolizumab in Localized Bladder Cancer
Role: collaborator
Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors
Role: collaborator
A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
Role: collaborator
All 13 trials loaded